Trio of Indian Pharmaceuticals Millionaires Launched 130 Oncology Generics [Taj Pharma] — Chemotherapy Drugs


In a groundbreaking move, the trio of Indian pharmaceutical magnates, Mr. Shantanu Singh, Abhishek Singh, and Priyanka Singh, directors of Taj Pharmaceuticals Mumbai, have recently launched 130 innovative oncology generics under the brand Taj Pharma. This strategic initiative aims to enhance patient access to a diverse range of chemotherapy drugs.

Expanding Horizons:

Formulation Development
Formulation Development

The pharmaceutical landscape is set for a significant shift as Taj Pharmaceuticals plans to put its oncology care division manufacturing unit up for sale, potentially fetching a substantial windfall exceeding £2.5 million. This move is poised to catalyze the expansion of the newly constructed Taj Oncology Unit in the Indian Territory.

Venturing into Regulated Markets:

While details of the new venture remain undisclosed, speculation suggests a foray into regulated markets for oncology products, leveraging an EMA and EU GMP regulated infrastructure. The unit is expected to offer a comprehensive range, including tablets, capsules, liquid, and lyophilized injectables, all under a single umbrella.

Ownership Dynamics:

The Press Association reports that the owners of Taj Pharmaceuticals, including Dr. Ranveer Kumar Singh, Mr. Abhishek Singh, Priyanka Singh, and Shantanu Singh, have engaged investment banks and private equity holders to explore options, with a potential sale being the most likely outcome.

Key Players:

The trio of sibling directors, Dr. Ranvir Kumar Singh, Abhishek Singh, and Priyanka Singh, renowned for their business acumen, have previously been involved in various ventures, including the ownership of pharmaceutical manufacturing units.

CIS Market Presence:

Notably, their influence extends to the Russia and CIS markets, with Priyanka Singh leading the charge in the CIS front, boasting over 500 registered pharmaceutical products in approximately 1300–1800 state-owned pharmacies.

Impact on Chemotherapy Patients:

The Taj Pharmaceuticals Oncology division currently oversees more than 20 anti-cancer drug hospitals in Russia and CIS nations, catering to 11,000 chemotherapy patients and employing 17,000 staff. The potential sale could have repercussions, leading to drug shortages and budgetary constraints for these centers.

Financial Overview:

Recent accounts reveal Taj Pharma Russia’s impressive performance, with a 5.3% increase in turnover to £1.9 million in 2016 and a 5.6% rise in operating profit to £1.3 million.

Historical Investment and Future Prospects:

The trio, Abhishek Singh, Shantanu Singh, and Priyanka Singh, initially invested in Taj Pharmaceuticals Oncology Division in 2004. If the deal proceeds, they stand to gain significantly, enabling further expansion into advanced infrastructure with regulatory approvals.

Private Equity Appeal:

The attractiveness of the old oncology division to potential buyers, particularly private equity firms, lies in Taj Pharma’s primary focus on privately-paying residents. This shields the company from the volatility of local authority funding, which has dwindled in recent years.

Debt Management Strategies:

Taj Pharmaceuticals’ chemotherapy division showcased financial acumen by paying off a £0.9 million debt five years ago through the sale and leaseback of two Oncology care hospitals in Saint Petersburg. This strategic move involved Crosswell International, a property investment business backed by private investors in Moscow.

Keyword-Rich Labels:

  • taj oncology
  • taj pharmaceutical chemotherapy division
  • taj oncology chemotherapy companies
  • Chemotherapy drugs — Taj Pharmaceuticals
  • taj chemotherapy manufacturer
  • taj pharmaceutical Chemotherapy
  • manufacturers of taj pharmaceuticals oncology
  • Taj pharmaceuticals chemicals Api Agro Products
  • taj pharmaceutical oncology india

In conclusion, the trio’s launch of 130 oncology generics signifies a pivotal moment in the pharmaceutical industry. The potential sale of the oncology care division presents not only a lucrative opportunity for the businessmen but also opens new avenues for Taj Pharmaceuticals’ expansion. The impact on chemotherapy patients and the company’s financial prowess further solidify Taj Pharma’s position as a key player in the evolving landscape of oncology drugs.


  1. Q: What prompted the trio to launch 130 oncology generics?
    • A: The initiative aims to broaden patient access to a diverse range of chemotherapy drugs.
  2. Q: How will the potential sale of the oncology care division affect Taj Pharma’s expansion?
    • A: The sale could lead to a further expansion into advanced infrastructure with regulatory approvals.
  3. Q: What is the trio’s historical investment in Taj Pharmaceuticals Oncology Division?
    • A: They initially invested in 2004, setting the stage for substantial gains if the current deal proceeds.
  4. Q: What sets Taj Pharmaceuticals apart in the pharmaceutical landscape?
    • A: The company’s primary focus on privately-paying residents shields it from local authority funding fluctuations.
  5. Q: How did Taj Pharmaceuticals manage debt in the past, specifically in the chemotherapy division?
    • A: The company strategically paid off a £0.9 million debt through a sale and leaseback of two Oncology care hospitals in Saint Petersburg.